Malign plevral efüzyonda cerrahi tedavi

Malign plevral efüzyon, plevral sıvı veya dokuda kanser hücrelerinin saptanması ile birlikte plevral boşlukta önemli miktarda eksüdat birikmesi olarak tanımlanır. İlerlemiş hastalığın bir göstergesidir ve sağkalım süresi 3 ila 12 ay arasında değişir. Malign plevral efüzyon için tedavi seçenekleri asemptomatik hastalarda gözlemden ağır hastalarda plörektomi ve hatta ekstraplevral pnömonektomiye kadar değişkenlik gösterir.

Surgical treatment in malignant pleural effusion

of exudate in the pleural space, accompanied by the detection of cancer cells in pleural fluid or tissue, which is the indicator of the disease in its advance stages, and survival time of these patients ranges between 3 and 12 months. Treatment options for malignant pleural effusion vary from observation in asymptomatic patients to pleurectomies or even extrapleural pneumonectomies in severe cases.

PDF

___

1. Thomas R, Kalomenidis I, Jett J, Gary Lee YC. Effusion from malignant causes. In: Light RW, Gary Lee YC, editors. Textbook of pleural diseases. New York: Taylor & Francis Group, LLC; 2016. p. 278-94.
2. Hudson JL, Puri V. Malignant pleural effusions. In: LoCicero J, Feins RH, Colson YL, Rocco G, editors. General thoracic surgery. Philadelphia: Wolters Kluwer; 2019. p. 8242-366.
3. Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989;2:366-9.
4. Özdemir E. Plevra ve plevral sıvının fizyolojisi. In: Şahin E, Karadayı Ş, Katrancıoğlu Ö, editörler. Her yönüyle plevra ve hastalıkları. Sivas: Cumhuriyet Üniversitesi Yayınları; 2018. s. 35-47.
5. Miserocci G, Beretta E, Grasso GS. Mechanics and fluid dynamics of lung and pleural space. In: LoCicero J, Feins RH, Colson YL, Rocco G, editors. General thoracic surgery. Philadelphia: Wolters Kluwer; 2019. p.7158-223.
6. Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol 2010;5:1544-50.
7. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score. Thorax 2014;69:1098-104.
8. Kara M, Alzafer S, Okur E, Halezeroglu S. The use of single incision thoracoscopic pleurectomy in the management of malignant pleural effusion. Acta Chir Belg 2013;113:270-4.
9. Çelik B, Demircan S, Bek Y, Başoğlu A . Malign plevral effüzyonda farklı plörodezis yöntemleri ile talk ve oksitetrasiklinin karşılaştırılması. Turkish J Thorac Cardiovasc Surg 2004;12:172-9.
10. Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-15.
11. Fysh ET, Tan SK, Read CA, Lee F, McKenzie K, Olsen N, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013;68:594-6.
12. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996;110:1387-93.
13. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA 2012;307:2383-9.
14. Putnam JB Jr, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999;86:1992-9.
15. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006;129:362-8.
16. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: A systematic review. J Gen Intern Med 2011;26:70-6.
17. Fysh ETH, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: An international multicenter study. Chest 2013;144:1597-602.
18. Little AG, Kadowaki MH, Ferguson MK, Staszek VM, Skinner DB. Pleuro-peritoneal shunting. Alternative therapy for pleural effusions. Ann Surg 1988;208:443-50.
19. Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000;18:143-6.
20. Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997;17:4743-6.
21. Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr, et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686-93.
22. Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol 2012;7:1485-9.
23. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J 2013;41:1409-18.
24. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11.
25. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
26. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-59.
27. Lucchi M, Davini F, Ricciardi R, Duranti L, Boldrini L, Palmiero G, et al. Management of pleural recurrence after curative resection of thymoma. J Thorac Cardiovasc Surg 2009;137:1185-9.
28. Moser B, Fadel E, Fabre D, Keshavjee S, de Perrot M, Thomas P, et al. Surgical therapy of thymic tumours with pleural involvement: An ESTS Thymic Working Group Project. Eur J Cardiothorac Surg 2017;52:346-55.
29. Fiorelli A, D'Andrilli A, Vanni C, Cascone R, Anile M, Diso D, et al. Iterative surgical treatment for repeated recurrences after complete resection of thymic tumors. Ann Thorac Surg 2017;103:422-31.
30. Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg 2006;82:1234-9.
31. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer 1975;35:734-8.
32. Rawindraraj AD, Zhou CY, Pathak V. Delayed breast cancer relapse with pleural metastasis and malignant pleural effusion after long periods of disease-free survival. Respirol Case Rep 2018;6:e00375.
33. Agrawal A, Sahni S, Iftikhar A, Talwar A. Pulmonary manifestations of renal cell carcinoma. Respir Med 2015;109:1505-8.
34. Renshaw AA, Comiter CV, Nappi D, Granter SR. Effusion cytology of renal cell carcinoma. Cancer 1998;84:148-52.
35. Kataoka M, Yata Y, Nose S, Yasuda K, Ohara T. Solitary pleural metastasis from renal cell carcinoma: A case of successful resection. Surg Case Rep 2015;1:36.
36. Bettenhausen A, Hamaji M, Burt BM, Ali SO. Pleurectomy and decortication for metastatic renal cell carcinoma. J Thorac Cardiovasc Surg 2015;150:e3-5.
37. Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D. Pleural effusions in hematologic malignancies. Chest 2004;125:1546-55.
38. Hirai S, Hamanaka Y, Mitsui N, Morifuji K, Sutoh M. Primary malignant lymphoma arising in the pleura without preceding long-standing pyothorax. Ann Thorac Cardiovasc Surg 2004;10:297-300.
39. Diaz JP, Abu-Rustum NR, Sonoda Y, Downey RJ, Park BJ, Flores RM, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 2010;116:483-8.
40. Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer--a preliminary report. Gynecol Oncol 2002;84:315-20.
41. Terauchi F, Kobayashi Y, Nagashima T, Moritake T, Nishi H, Fujito A, et al. Pilot study on transdiaphragmatic thoracoscopicassisted pleural biopsy and intrathoracic washing cytology for Stage IIIc ovarian cancer with diaphragmatic metastases. Int J Gynecol Cancer 2009;19:300-3.